Connect with us

Covid19

Interim Infection Prevention and Control Guidance for Veterinary Clinics During the COVID-19 Response

Avatar

Published

on

Key Concepts

  • This interim guidance is for veterinarians and their staff who may be treating or advising on companion animal medical care during the COVID-19 pandemic.
  • Veterinary facilities have unique characteristics that warrant unique infection control considerations.
  • At this time, there is no evidence that companion animals play a significant role in spreading SARS-CoV-2, the virus that causes COVID-19. Based on the limited data available, the risk of animals spreading COVID-19 to people is considered to be low. We are still learning about this virus, and it appears that in some rare situations, people can spread the virus to animals. Further studies are needed to understand if and how different animals could be affected by the virus, and the role animals may play in the spread of COVID-19.
  • To protect staff and preserve personal protective equipment (PPE) and supplies during the COVID-19 pandemic, veterinary clinics should prioritize urgent and emergency visits and procedures until regular business operations resume in your community. Curbside service and telemedicine can be effective options to support patient care while social distancing.
  • Proactively communicate to both staff and pet owners the need for them to stay at home if sick.
  • Develop a plan for what to do if a pet owner with respiratory symptoms comes into your clinic, or if a pet with a history of exposure to a person with suspected or confirmed COVID-19 needs to be seen.

Who this guidance is for: Veterinarians and veterinary staff providing care to companion animals

Purpose: The intent of this guidance is to facilitate preparedness and to ensure practices are in place in a companion animal veterinary clinical setting to help people and animals stay safe and healthy.

This interim guidance is based on what is currently known about the transmission and severity of coronavirus disease 2019 (COVID-19). This is a rapidly evolving situation. CDC will update this guidance as needed, and as additional information becomes available. States may have their own specific requirements for these circumstances. Please check the CDC COVID-19 website periodically for updated information as well as interim guidance.

Veterinarians should use their best clinical judgement when evaluating companion animals and considering appropriate PPE to use and precautions to take.

Note: The scientific name of this novel coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In people, the disease caused by the virus is called Coronavirus Disease 2019, or COVID-19. In the context of animal health, we refer to the disease as SARS-CoV-2.

What do we currently know about animals and COVID-19?

SARS-CoV-2, the virus that causes COVID-19 in humans, is thought to be spread primarily through respiratory droplets from coughing, sneezing, or talking. There are also reports that people may be able to spread the virus while pre-symptomatic or asymptomatic. We are still learning about this novel zoonotic virus, and it appears that in some rare situations, human to animal transmission can occur.

CDC is aware of a small number animals, including dogs and cats, reportedexternal icon to be infected with SARS-CoV-2 after close contact with people with COVID-19. The United States Department of Agriculture (USDA) and CDC recently reported confirmed infection with SARS-CoV-2 in two pet cats with mild respiratory illness in New York, which were the first confirmed cases of SARS-CoV-2 infections in companion animals in the United States. Both cats are expected to recover. The cats had close contact with people confirmed or suspected to have COVID-19, suggesting human-to-cat spread. Further studies are needed to understand if and how different animals could be affected by SARS-CoV-2.

Limited information is available to characterize the spectrum of clinical illness associated with SARS-CoV-2 infection in animals. Clinical signs thought to be compatible with SARS-CoV-2 infection in animals include fever, coughing, difficulty breathing or shortness of breath, lethargy, sneezing, nasal/ocular discharge, vomiting, and diarrhea.

Advise veterinary clinic staff who are sick to stay home

Follow CDC’s guidance on what to do if you are sick. Ask staff to stay home if they are sick.  Employees who appear to have symptoms (e.g., fever, cough, or shortness of breath) upon arrival at work or who become sick during the day should immediately be separated from other clinic employees, customers, and clients and sent home. Inform the staff’s team members if they have been exposed to someone who might have COVID-19, while maintaining confidentiality as required by the Americans with Disabilities Act. Notify the local health department of the potential exposure as well. Ill staff should not return to work until their fever (defined as ≥100.4°F) is absent for at least 72 hours without the use of fever-reducing medication, other symptoms have improved, and at least 10 days have passed since symptom onset.

Implement sick leave policies for veterinary clinic staff that are flexible, nonpunitive, and consistent with public health guidance, allowing employees to stay home if they have symptoms of respiratory infection.

Follow CDC guidelines for cleaning and disinfecting areas the sick employee visited. If possible, staff should each have their own workspace/equipment and avoid sharing desks/work tools. If these items must be shared, they should be frequently disinfected.

Critical workers, like veterinarians and their staff, can be permitted to continue to work following a potential exposure to COVID-19, provided they remain asymptomatic and additional precautions are implemented to protect them and the workplace. Everyone who enters the clinic, including employees and visitors, should wear a cloth face covering over their nose and mouth to contain respiratory secretions, unless engaged in an activity that requires a different form of PPE.

Postpone non-urgent veterinary visits and elective procedures until regular business operations resume in your community

Most jurisdictions recognize veterinary practices as essential and are allowing them to operate during the COVID-19 pandemic. To protect staff and preserve personal protective equipment (PPE) and supplies during the COVID-19 pandemic, veterinary clinics should make considerations to protect both human and animal health. Veterinarians should apply careful professional judgement to case management so that needed care for animals continues to be provided while limiting staff and client person-to-person exposure and conserving PPE. This may also include prioritizing urgent patient visits and postponing non-urgent veterinary visits and elective procedures until regular business operations resume in your community. In some jurisdictions executive orders will directly influence what types of procedures may be performed.

The greatest risk of COVID-19 exposure to staff at veterinary clinics comes from person-to-person transmission through respiratory droplets from coughing, sneezing, or talking, which is the main way SARS-CoV-2 spreads. Clinic staff should be screened daily, at the beginning of shifts prior to interacting with staff and clients, and should practice social distancing. Clinics should take precautions to minimize staff contact with all pet owners. Examples of actions to take to minimize contact with pet owners or other people include:

  • Using professional judgement when determining whether a case is urgent or non-urgentexternal icon and when procedures should be postponed.
  • Using telemedicine for consults or to help triage patients. Consult your state requirements for telemedicine and veterinary-client-patient relationship (VCPR) requirements.
  • Scheduling drop-off appointments or receiving companion animals from their owners’ vehicles (also called curbside).
  • Communicating via telephone or video-chat to maintain social distancing.
  • Using direct-to-exam-room admissions or enforcing social distancing in the lobby.
  • Having staff members, rather than clients, hold animals to minimize direct contact.
  • Using online payment and billing to reduce handling credit cards or other potential fomites.

Have a plan in place to handle animals with confirmed or suspected COVID-19 exposure, or potentially compatible clinical signs. Veterinarians should contact their state public health veterinarianpdf iconexternal icon or state animal health officialexternal icon for guidance on testing animals for SARS-CoV-2 infection.

Screen companion animals for exposure to people with COVID-19

Before scheduled appointments or upon arrival, a staff person should ask if the pet has had any exposure to a person with suspected or confirmed COVID-19.

Know actions to take if a pet owner has suspected or confirmed COVID-19

If a pet owner currently has respiratory symptoms or is a suspected of or confirmed to have COVID-19, they should not visit the veterinary facility. Consider whether a telemedicine consult is appropriate. If possible, a healthy friend or family member from outside their household should bring the animal to the veterinary clinic. The clinic should use all appropriate precautions to minimize contact with the person bringing the animal to the clinic. If there is an emergency with the animal, the animal should not be denied care.

  • If a pet owner is suspected or confirmed to have COVID-19 and must bring their pet to the clinic, the following actions should be taken:
    • Communicate via phone call or video chat to maintain social distancing.
    • Retrieve the animal from the owner’s vehicle (also called curbside) to prevent the owner from having to enter the clinic or hospital.
    • Maintain social distancing and PPE recommendations when interacting with clients.
    • Request smaller animals be brought in a plastic carrier to facilitate disinfection of the carrier after use. Also advise the owner to leave all non-essential items at home to avoid unnecessary opportunities for additional exposure.
  • Every effort should be made to prevent ill persons from entering the clinic, without negatively impacting animal welfare
    • If an ill pet owner must enter the clinic:
      • Have the person wear a cloth face covering over his or her nose and mouth. Be prepared to provide a face covering to the ill person if they do not have their own.
      • Direct the pet owner and patient to a single exam room or isolation room.
      • Limit the number of veterinary staff that enter the room, handle the animal, or interact with the pet owner and wear appropriate PPEpdf icon as described below.
      • Clean and disinfect the room, surfaces, supplies, floor, and equipment located within 6 feet of ill pet owners after they leave.
    • If you are a mobile or house call veterinarian and are called upon to evaluate a sick or injured companion animal in the home of a COVID-19 patient:
      • Enter the home only if absolutely necessary. AVMAexternal icon suggests that mobile and house call veterinarians consider examining companion animals in their vehicle, outside, or seek the assistance of a local clinic. If you must enter the home where someone is sick with COVID-19, wear appropriate PPEpdf icon.
      • PPE should be donned before entering the home and removed only after leaving the home, following appropriate donning and doffing procedurespdf icon.
      • If there is a sick person in the home, ask the sick person(s) to confine themselves to another room in the house if possible. If not possible, ask them to wear a cloth face covering and maintain a distance of at least 6 feet (2 meters). Be prepared to provide a face covering to the ill person if they do not have their own. Minimize contact with other household members, even if they appear healthy, as person-to-person transmission can occur before symptom onset.
      • Wash hands immediatelypdf icon after removing PPE, handling the animal, or interacting with a sick person or household contact. If soap and water are not readily available, use a hand sanitizer that contains at least 60% alcohol. Cover all surfaces of your hands and rub them together until they feel dry.
    • Critical workers, like veterinarians and their staff, can be permitted to continue to work following a potential exposure to COVID-19, provided they remain asymptomatic and additional precautions are implemented to protect them and the workplace.

Clinical signs in animals

The clinical spectrum of illness for the SARS-CoV-2 virus remains largely undefined in animals. Companion animals may present with respiratory or gastrointestinal clinical signs based on the presentation of other coronaviruses more commonly found in animals as well as other emerging coronaviruses, including SARS-CoV-1 infection.

Clinical signs more likely to be compatible with SARS-CoV-2 infection in mammalian animals may include a combination of the following:

  • Fever
  • Coughing
  • Difficulty breathing or shortness of breath
  • Lethargy
  • Sneezing
  • Nasal discharge
  • Ocular discharge
  • Vomiting
  • Diarrhea

Personal protective equipment (PPE)

Given current limitations in knowledge regarding COVID-19 and companion animals, these PPE guidelines use a cautious approach. Recommendations may change over time, as new information becomes available. Veterinarians should use their professional judgement regarding potential for exposure to COVID-19 and PPE resource constraints when determining the appropriate PPE precautions to apply.

Animal History Facemask Eye Protection (face shield, goggles) Gloves Protective Outerwear (gown or coveralls3) N95 Respirator or Suitable Alternative4
Recommended Personal Protective Equipment (PPE) Based on Companion Animal History
Healthy companion animal without exposure to a person with COVID-19 compatible symptoms1, 2 N1 N1 N1 N1 N1
Companion animal with an illness that is not suspicious of SARS-CoV-2 infection5 AND without exposure to a person with COVID-19 compatible symptoms1, 2 N1 N1 N1 N1 N1
Companion animal that is not suspicious of SARS-CoV-2 infection5  BUT has exposure to a person with COVID-19 compatible symptoms Y N1 Y N1 N1
Companion animal with an illness that is suspicious of SARS-CoV-2 infection5 Y Y Y Y N7
Aerosol-generating procedure for any animal without an exposure to a person with COVID-19 compatible symptoms6 Y Y Y Y N7
Aerosol-generating procedure for any animal with an exposure to a person with COVID-19 compatible symptoms6 N Y Y Y Y
Any procedure on an animal that is known to be currently infected with SARS-CoV-2 through detection by a validated RT-PCR assay N Y Y Y Y
Any procedure where a person with suspected or confirmed COVID-19 will be present N Y Y Y Y

1PPE Standard Precautions should be applied in any setting where veterinary care is delivered and if exposure to fluids, exudates, feces, saliva, or other animal fluids is possible.

2A SARS-CoV-2 or COVID-19 exposure in this context refers to the following conditions within the 14 days prior to presenting for veterinary care:

  • Being within approximately 6 feet (2 meters) of a person with suspected or confirmed COVID-19; close contact can occur while an animal is living with, being pet, snuggled, giving kisses or licks, and/or sharing food or bedding with a person.
  • Having direct contact with infectious secretions from a person with suspected or confirmed COVID-19 (e.g., being coughed, sneezed or spit on, sharing food or consuming an object that was recently contaminated with an infected person’s mucous or saliva).

3Reusable (i.e., washable) gowns are typically made of polyester or polyester-cotton fabrics. Gowns of these fabrics can be safely laundered according to routine procedures and reused.

4Respiratory protection that is at least as protective as a fit-tested NIOSH-certified disposable N95 filtering facepiece respirator is recommended.

  • If an N95 respirator is not available, use a combination of a surgical mask and a full face shield.
  • Respirator use should be in the context of a complete respiratory protection program in accordance with OSHA Respiratory Protection standard (29 CFR 1910.134), which includes medical evaluations, training, and fit testing.

5 Clinical signs expected to be compatible with possible SARS-CoV-2 infection in companion animals may include:

Source: https://tools.cdc.gov/api/embed/downloader/download.asp?m=403372&c=406502

Covid19

Global COVID-19 Deaths Top 3 Million

Avatar

Published

on

Relatives attend a COVID-19 victim’s burial at a cemetery in Manaus, Amazonas state, Brazil, on Thursday. Michael Dantas/Getty Images hide caption

toggle caption

Michael Dantas/Getty Images

Global deaths from COVID-19 has surpassed 3 million, according to the latest data from John Hopkins University.

Leading in those deaths are the United States, with more than 566,000, and Brazil, with more than 368,000. They are followed by Mexico, India and the United Kingdom.

The global death toll reached 1 million in September 2020 and 2 million in January.

The grim milestone comes after health officials in the U.S. paused rollout of the single-dose Johnson & Johnson vaccine after six women experienced rare but severe blood clots a week or two after receiving it.

Overall, more than 129 million people in the U.S. have received at least one dose of COVID-19 vaccine, including 7.8 million doses of the J&J vaccine. More than 82 million Americans — nearly 25% of the population — have been fully vaccinated.

In Brazil, deaths have topped 3,000 per day as the country is ravaged by the virus. Mexico has recorded more than 211,000 deaths. India has had more than 175,000 deaths and deaths in the United Kingdom have topped 127,000.

COVID-19 variants are spreading throughout the U.S., with the more contagious U.K. variant, B.1.1.7, now dominant. On Friday, the Biden administration announced plans to spend $1.7 billion on combating and tracking variants.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.npr.org/sections/coronavirus-live-updates/2021/04/17/988386358/global-covid-19-deaths-top-3-million

Continue Reading

Covid19

KFF COVID-19 Vaccine Monitor: What We’ve Learned

Avatar

Published

on

The KFF COVID-19 Vaccine Monitor is an ongoing research project tracking the public’s attitudes and experiences with COVID-19 vaccinations. Using a combination of surveys and qualitative research, this project tracks the dynamic nature of public opinion as vaccine development and distribution unfold, including vaccine confidence and acceptance, information needs, trusted messengers and messages, as well as the public’s experiences with vaccination.

KFF launched the COVID-19 Vaccine Monitor in December 2020 to track the dynamic nature of the U.S. public’s attitudes and experiences with COVID-19 vaccination as distribution efforts unfold across the country. As many states have opened up eligibility to everyone ages 16 and over and the remainder of states are poised to do so soon, this brief summarizes some of the key findings and themes from this research based on interviews with more than 11,000 adults across the nation to date.

Key takeaways

  • Broadly, the COVID-19 Vaccine Monitor has found that vaccine confidence in the U.S. has increased as more and more people have seen their friends and family members get vaccinated, and now a majority of the public has either already gotten vaccinated or is ready to get the vaccine as soon as they can. Yet with a small but persistent group opposed to getting the vaccine and many others still on the fence, the U.S. may soon hit a point where vaccine supply exceeds demand, a situation that is already the case in certain communities.
  • While some media narratives have focused on which groups are most “vaccine hesitant,” our research finds that no group is monolithic in their vaccine attitudes, and in every demographic segment there are large shares of people who are ready to get the vaccine, others who are in “wait and see” mode, and some who are more resistant. Even though certain demographics (for example, Republicans) have a higher share than other groups saying they don’t intend to get vaccinated and others (for example, Black adults) have a higher share saying they want to “wait and see,” we’ve found that majorities across all demographic groups are at least somewhat open to getting the vaccine.
  • Those who are not ready to get vaccinated for COVID-19 right away have a range of questions and concerns about the vaccine that require different strategies to address. The top concern across groups has been the potential side effects of the vaccine, including a substantial share who are worried about missing work due to side effects. Other concerns reflect a lack of access to accurate information; for example, many are concerned that they might get COVID-19 from the vaccine (which is not possible) or that they will have to pay out-of-pocket costs to get vaccinated (when in fact, vaccination is free). And other concerns reflect issues with vaccine access, including needing to take time off work to get vaccinated, issues with transportation, or concern about not being able to get the vaccine from a trusted place. Rather than a single messaging strategy, these concerns point to the need for a combination of information, outreach, and policies to both bolster confidence in COVID-19 vaccines and make vaccination accessible across communities.
  • Individual health care providers are the most trusted messengers when it comes to information about the COVID-19 vaccines. With trust in national public health messengers eroding and becoming increasingly partisan over the past year, local doctors, nurses, health care providers, and other trusted community figures have an important role to play in supplementing any national campaigns to increase COVID-19 vaccine confidence and uptake.
  • It is too early to know what effect the recent announcement about the pause in distribution of the Johnson & Johnson vaccine will have on COVID-19 vaccine confidence. Prior to this announcement, our research found that the one-shot vaccine was an appealing option for a large share of those in the “wait and see” group. However, the potential side effects of the vaccine are a top concern for those who have not yet been vaccinated, so if the public perceives blood clots as a potential side effect (regardless of whether a link is proven), this news does have the potential to increase concerns about getting the Johnson & Johnson vaccine. In the meantime, messages about the effectiveness of the existing vaccine options at preventing serious illness and death from COVID-19 are likely to be the most effective at bolstering confidence among those who are on the fence about getting the vaccine.

Vaccination intentions: trends and demographics

  • The share of the public that is eager to get the COVID-19 vaccine has been increasing over time, including across subgroups by race/ethnicity, partisanship, and urbanicity. As of March, six in ten adults said they had already gotten at least one dose of the vaccine (32%) or would get it as soon as it was available to them (30%), a share that has increased steadily since December, when 34% said they would get the vaccine as soon as possible. The share saying they want to “wait a while and see how it’s working for others” before getting vaccinated themselves declined steadily from 39% in December to 17% in March. Where we have not yet seen much movement is in the shares saying they definitely won’t get the vaccine (13% in March) or will do so only if required for work, school, or other activities (7%).
  • People at higher risk for serious complications and death from COVID-19 tend to be more enthusiastic about getting the vaccine. For example, in March, 82% of adults ages 65 and older and 70% of individuals with a serious health condition say they’ve already been vaccinated or will get the vaccine as soon as they can, compared to smaller shares of younger adults and those without serious health conditions. This at least partially reflects early access these groups had to the vaccine compared to others, but also the fact that larger shares of younger and healthier adults say they want to wait and see, will get the vaccine only if required, or will definitely not get vaccinated.
  • While enthusiasm for getting the vaccine increased dramatically among Black adults between February and March (from 41% to 55% saying they’d already gotten vaccinated or intended to do so as soon as possible), Black adults remain somewhat more likely than White adults to say they want to “wait and see” (24% vs. 16%). In earlier months, Hispanic adults were also somewhat more likely to say they wanted to “wait and see,” but by March the share among Hispanic adults decreased to 18%.
  • Education is also a dividing factor in vaccination intentions, with college-educated adults more likely than those without college degrees to say they’ve already gotten vaccinated or will do so as soon as they can (73% vs. 56% in March).
  • Vaccination intentions have also divided along party lines since December, reflecting the broader partisan dialogue about the pandemic over the past year. About eight in ten Democrats (79%) are eager to get the vaccine or say they have done so already, compared to nearly six in ten independents (57%) and just under half of Republicans (46%). About three in ten Republicans (29%) say they will “definitely not” get vaccinated, a share that has not changed substantially over time.
  • In addition, 28% of White Evangelical Christians say they will definitely not get the vaccine, reflecting the fact that two-thirds (66%) of this group either identifies as Republican or leans towards the Republican party. One in five rural residents also say they will definitely not get vaccinated, about twice the share as in urban areas, a gap largely explained by the concentration of Republicans and White Evangelical Christians who live there.

Challenges and opportunities that cross demographic groups

Concerns and messages

  • The potential side effects and the newness of the vaccine seem to be driving a lot of the concern among people who have not yet been vaccinated. Among the 37% of adults in March who were not yet convinced to get the vaccine as soon as possible, seven in ten said they were concerned they might experience serious side effects from the vaccine, and over six in ten were concerned the effects of the vaccine might be worse than getting COVID-19. In addition, when those who say they will definitely not get the vaccine are asked to state their main reason in their own words, the most common response is that the vaccine is too new and/or that not enough is known about the long-term effects.
  • Different groups respond to messaging and information at different levels, but of the messages we’ve tested, emphasizing the effectiveness of the vaccine at preventing serious illness and death is the most effective across groups (two-thirds of those in the “wait and see” group and four in ten in the “only if required” group say they’d be more likely to get vaccinated after hearing the vaccines are nearly 100% effective at preventing hospitalizations and death from COVID-19).
  • The “wait and see” group is an important target for outreach and messaging, since they express some concerns about getting vaccinated, but will likely be much easier to convert from vaccine-hesitant to vaccine-acceptant than those who say they will “definitely not” get the vaccine or will get it “only if required” to do so. Other messages/information that are effective at persuading many in the “wait and see group” include that scientists have been working on the technology used in the new COVID-19 vaccines for 20 years; that more than 100,000 people from diverse backgrounds took part in the vaccine trials; that the vast majority of doctors who have been offered the vaccine have taken it; and that there is no cost to get the vaccine.
  • Separate from concerns about the effects of the vaccine itself, about six in ten of those who are not yet convinced to get the vaccine right away are concerned that they might be required to get the vaccine even if they don’t want to.

Information and misinformation

  • Reaching people with information about how to access vaccines is an ongoing challenge. As of March, many people say they still don’t have enough information about when (46%) and where (33%) they’ll be able to get the vaccine, and three in ten are not sure if they are currently eligible in their state (rising to four in ten among Hispanics, young adults, and those with lower incomes).
  • Many are unaware of some basic facts about the vaccines and how they work. As of January, 34% of all those who had not been vaccinated had heard and believed or were unsure about several common “myths” about the vaccine (that it contains the live virus that causes COVID-19, that it causes infertility, or that one must pay out-of-pocket to get vaccinated), rising to 41% among the “wait and see” group and 53% among those who say they will “definitely not” get vaccinated. Around four in ten of those who are not yet convinced to get the vaccine right away (rising to half among Black and Hispanic adults) are concerned that they might get COVID-19 from the vaccine.
  • Health care providers are the top source people say they will turn to for information when making decisions about whether to get vaccinated (79%, far outranking other sources in January). However, just one-quarter of those who had not yet been vaccinated said they have asked a provider about the vaccine as of February. Regardless of the sources they trust or say they will turn to, the media is a more prominent source where people are actually getting information. Asked where they have gotten information about the vaccine in recent weeks, cable (43%), network (41%), and local TV news (40%) are top sources, along with family and friends (40%). However, social media, most notably Facebook, is among the most prominent sources of information for those who want to “wait and see” about the vaccine (37%) as well as those who say they “definitely won’t” get vaccinated (40%).

Vaccine access and experiences

  • While most of those who were vaccinated as of February say they were able to find or schedule a vaccine appointment on their own, about four in ten say someone else helped them, including larger shares of those with lower incomes and without college degrees. Among those who believe they are eligible but had not yet been vaccinated as of March, about a third have tried to schedule a vaccination appointment including 16% who did so successfully and 17% who say they tried but were unable to make an appointment.
  • Making access to vaccines more convenient may improve uptake among some groups. Among the “wait and see” group, half say they’d be more likely to get vaccinated if their doctor offered it during a routine appointment, and four in ten of those with jobs say they’d be more likely to get it if their employer arranged for them to get vaccinated at work. Employer incentives could also play a role (38% of the employed “wait and see” say they’ be more likely to get vaccinated if their employer paid them $200), as could airline travel requirements (almost half in both the “wait and see” and “only if required” groups say they’d be more likely to get vaccinated if it was required to fly).

Challenges and opportunities for key subgroups

Despite the demographic differences in vaccination intentions noted above, no group is monolithic in their attitudes towards the COVID-19 vaccines. In each demographic group, there are many who are eager to get the vaccine right away and some who say they won’t get it under any circumstances. Importantly, across all the groups we’ve analyzed, a large majority is at least somewhat open to getting the vaccine and no more than one-third say they will “definitely not” get it. Still, our in-depth survey work has revealed some insights that may be helpful for those looking to understand vaccine attitudes and increase confidence in specific populations, and those are outlined in the sections below.

Black and Hispanic adults

  • Concern about getting sick with COVID-19 is high among Black and Hispanic adults who want to wait and see before getting vaccinated, but concern about experiencing serious side effects of the vaccine is also high. Given this, messages focused on protecting individuals and families from illness, while also acknowledging and/or addressing concerns about serious side effects may be most successful.
  • People express a range of other concerns about the vaccine that can be addressed with better access to information and policies that make it easier for people to get the vaccine from trusted places, and many of these concerns are expressed at higher rates among people of color. In particular, among those who are not convinced to get the vaccine as soon as possible, at least half of Black and Hispanic adults are concerned that they might get COVID from the vaccine or that they might have to miss work if they have side effects. Addressing these misperceptions in conversations and outreach may be helpful.
  • For Black adults in particular, reluctance to get vaccinated may be related to mistrust of the health care system that reflects both historical mistreatment and personal experiences with racism and discrimination. In fact, 38% of Black adults and 27% of Hispanic adults who are not yet convinced to get the vaccine are worried they won’t be able to get it from a place they trust.
  • Black and Hispanic adults say they will turn to a wide range of information sources when making vaccine-related decisions, including individual health care providers, pharmacists, friends and family, and government health agencies. While religious leaders rank lower on the list of overall sources of information, among those who want to “wait and see,” Black adults (35%) and Hispanic adults (28%) are more likely than white adults (14%) to say they’ll turn to them for information, indicating a possible effective messenger to reach some the Black and Hispanic communities.

Republicans

  • While about a third of Republicans say they will “definitely not” get the vaccine or will get it “only if required,” another 19% are in “wait and see” mode and may be receptive to messages and information aimed at increasing vaccine uptake. However, even within the “wait and see” group, partisan differences emerge that suggest different messaging strategies will be required. For example, two-thirds (67%) of Republicans and Republican-leaning independents in the “wait and see” group view vaccination as a personal choice, and half (51%) believe the seriousness of COVID-19 is being exaggerated in the news, according to the January Monitor. This suggests that messages focused on helping people make the right choice to protect their own health are more likely to resonate with Republican audiences than those that emphasize the seriousness of the pandemic or the need to get vaccinated for the collective good.
  • Government sources of information (including the CDC and state and local health departments) are less trusted by Republicans than by Democrats in the “wait and see” group, so individual health care providers, pharmacists, and friends and family are a better conduit for messaging/information to Republicans.
  • Republicans – who tend to be particularly concerned about personal liberty – are more likely to be concerned about being required to get vaccinated against their will. Among those who are not convinced to get vaccinated right away, a larger share of Republicans (71%) compared to independents (57%) and Democrats (53%) say they are concerned that they might be required to get the vaccine even if they don’t want to.
  • Two-thirds (66%) of White Evangelical Protestants identify as Republicans or independents who lean toward the Republican Party, so there is a lot of overlap between their attitudes toward the COVID-19 vaccine and the attitudes of Republicans in general.

Rural residents

  • In a large survey of over 1,000 adults living in rural areas, we found signs of strong early uptake and access to vaccines in rural areas. A slightly larger share of adults in rural areas compared to urban and suburban areas reported having received at least one dose of the vaccine (39% vs. 31%), and an additional 16% of rural residents want to get the vaccine as soon as they can. In addition, most adults living in rural areas feel their community has enough vaccination locations and vaccine supply to serve local residents. However, Black adults living in rural areas are less likely than White or Hispanic adults to say their community has adequate supply of these things.
  • While one in five rural residents say they will “definitely not” get vaccinated, this is largely due to the disproportionate share of Republicans and White Evangelical Christians living in these areas. The concerns that rural residents have about the vaccine and the messages that resonate most to convince them to get vaccinated mirror the concerns and effective messages for the public at large.

The “definitely nots”

  • Those who say they will “definitely not” get the vaccine (13% of the overall public) have a very different view of the overall pandemic compared to the rest of the population. For example, 75% of this group believes the seriousness of coronavirus has been exaggerated by the media (compared to 32% of the public overall), and 82% are not worried about themselves or a family member getting sick from COVID-19 (compared to 50% of the public overall).
  • This group not only views the vaccine differently, but they also hold different views on other protective measures. For example, 96% of those in the “definitely not” group say getting vaccinated for COVID-19 is a personal choice rather than part of everyone’s responsibility to protect others (compared to 46% of the public overall who say this), and 65% believe that wearing a mask does not prevent the spread of coronavirus (compared with 20% of the public overall).
  • This group is highly distrustful of government sources of information; 83% say they trust the U.S. government “not too much” or “not at all” to look out for the interests of people like them, and 71% say they do not trust the CDC for reliable information about COVID-19 vaccines.
  • Of the messages and incentives we’ve tested to see what might make people more likely to get the vaccine, none are effective at moving more than a very small share of the “definitely not” group. For example, fewer than one in ten among this group say they’d be more likely to get vaccinated after hearing the vaccines are nearly 100% effective at preventing hospitalization and death from COVID-19 or that scientists have been working on the technology used in the vaccines for 20 years. A similarly small share say they’d be more likely to get vaccinated if airlines required it or if it was offered to them during a routine medical visit.

Frontline health care workers

  • A KFF/Washington Post survey of frontline health care workers, including those who work in various functions such as treating patients, performing administrative duties, or assisting with patient’s daily activities and housekeeping, found that half (52%) of all frontline health workers reported receiving at least one dose of a COVID-19 vaccine as of early March and another one in five (19%) had scheduled or were planning to receive the vaccine. Another nearly one in five (18%) said they did not plan to get vaccinated and 12% had not made up their mind.
  • As among the general public, COVID-19 vaccination intention among health care workers divides by race/ethnicity and education, as well as by work location and type of job duties. For example, while the large majority of those working in hospitals have been gotten the vaccine or intend to do so, almost half of those working in patients’ homes say they won’t get vaccinated or are undecided. And among physicians (and nurses with graduate degrees), nearly nine in ten report either already being vaccinated or plan to get a vaccine.
  • Health care employers have a role to play in making sure their employees can get vaccinated. The share of health care workers who were offered a COVID-19 vaccine from their employer was much lower among those working in patients’ homes compared to those working hospitals and other settings.
  • The potential side effects of the vaccine – a top concern among the public – are also a top concern for health care workers who have not yet been vaccinated; 82% say worry about possible side effects is a major factor in their decision about whether to get vaccinated.

This slideshow requires JavaScript.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-what-weve-learned-april-2021/

Continue Reading

Covid19

Vaccine Monitor: What We’ve Learned

Avatar

Published

on

With nearly all states poised to allow anyone at least 16 years old to get a COVID-19 vaccine, this week’s announcement pausing the distribution of the Johnson & Johnson vaccine to investigate a rare side effect is raising questions about whether and how it will affect the public’s eagerness to get vaccinated.

A new report summarizes key insights about vaccine confidence, messages and messengers from the KFF COVID-19 Vaccine Monitor project, which has interviewed more than 11,000 adults nationally since December to track the public’s shifting attitudes and experiences with COVID-19 vaccinations.

Among its key takeaways:

  • Among those who are not ready to get a COVID-19 vaccination right away, their top concern consistently has been the potential side effects, including many who worry they will have to miss work due to side effects. The news about the Johnson & Johnson vaccine could heighten those worries for people on the fence about getting vaccinated.
  • Prior to the pause in the Johnson & Johnson vaccine, it was an appealing option for a large share of those in the “wait and see” group because it requires only a single shot, while the other available vaccines (Moderna and Pfizer) require two shots several weeks apart.
  • Some people’s concerns about vaccination are based on lack of access to accurate information. For example, many are concerned that they might get COVID-19 from a vaccine, which is not possible, or that they will have to pay out-of-pocket even though the COVID-19 vaccinations are free.
  • No group is monolithic in their vaccine attitudes. While some demographics such as Republicans have a higher share saying they don’t intend to get vaccinated, and others such as Black adults have a higher share saying they want to “wait and see,” majorities across all demographic groups are at least somewhat open to getting a vaccine.
  • Individual health care providers are the most trusted messengers when it comes to information about the COVID-19 vaccines.

Available through the Monitor’s online dashboard, the report looks at common messages and messengers that apply across demographic groups, as well as challenges and opportunities related to the views of specific groups such as Black and Hispanic adults, Republicans, rural residents, frontline health workers and those who say they will “definitely not” get vaccinated.

The KFF COVID-19 Vaccine Monitor is an ongoing research project tracking the public’s attitudes and experiences with COVID-19 vaccinations. Using a combination of surveys and qualitative research, this project tracks the dynamic nature of public opinion as vaccine development and distribution unfolds, including vaccine confidence and acceptance, trusted messengers and messages, as well as the public’s experiences with vaccination.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.kff.org/coronavirus-covid-19/press-release/vaccine-monitor-what-weve-learned/

Continue Reading

Covid19

Recommendation to Pause Use of Johnson & Johnson’s Janssen COVID-19 Vaccine

Avatar

Published

on

Safety Is a Top Priority

COVID-19 vaccine safety is a top priority for the federal government, and all reports of health problems following COVID-19 vaccination are taken very seriously. This potential safety issue was caught early, and this pause reflects the federal government’s commitment to transparency as CDC and FDA review these data. COVID-19 vaccines have undergone and will continue to undergo the most intensive safety monitoring in U.S. history.

What to Do If You Received the J&J/Janssen COVID-19 Vaccine

If you received the vaccine more than three weeks ago, the risk of developing a blood clot is likely very low at this time.

If you received the vaccine within the last three weeks, your risk of developing a blood clot is also very low and that risk will decrease over time.

Contact your healthcare provider and seek medical treatment urgently if you develop any of the following symptoms:

  • severe headache,
  • backache,
  • new neurologic symptoms,
  • severe abdominal pain,
  • shortness of breath,
  • leg swelling,
  • tiny red spots on the skin (petechiae), or
  • new or easy bruising

If you are scheduled to get the J&J/Janssen COVID-19 Vaccine, please work with your vaccine provider to reschedule your appointment to receive another authorized and recommended COVID-19 vaccine. There are two other COVID-19 vaccines authorized and recommended for use in the United States: Pfizer-BioNTech and Moderna.

If you experience any adverse events after vaccination, report them to v-safe and the Vaccine Adverse Event Reporting Systemexternal icon.

For Healthcare Providers

Healthcare providers are recommended to pause the use of the J&J/Janssen COVID-19 Vaccine. Maintain acute clinical awareness of symptoms that might represent serious thrombotic events or thrombocytopenia in patients who have recently received the J&J/Janssen COVID-19 Vaccine, including:

  • severe headache,
  • backache,
  • new neurologic symptoms,
  • severe abdominal pain,
  • shortness of breath,
  • leg swelling,
  • petechiae, or
  • new or easy bruising.

Read the official CDC health alert, Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine, which includes details about how to handle a patient that presents with thrombosis or thrombocytopenia.

Report adverse events to the Vaccine Adverse Event Reporting Systemexternal icon.

For Vaccine Providers

Please work with individuals who were scheduled to receive the J&J/Janssen COVID-19 Vaccine in the days ahead to reschedule their appointments to receive another authorized and recommended COVID-19 vaccine (i.e., Pfizer-BioNTech, Moderna).

hand holding medical light icon

For Healthcare Workers

Clinical Resources: Toolkits and resources for handling, storing and administering the vaccine.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://tools.cdc.gov/api/embed/downloader/download.asp?m=404952&c=420600

Continue Reading
Esports5 days ago

Free Fire World Series APK Download for Android

Esports3 days ago

C9 White Keiti Blackmail Scandal Explains Sudden Dismissal

Esports3 days ago

Overwatch League 2021 Day 1 Recap

Esports5 days ago

Dota 2: Top Mid Heroes of Patch 7.29

Esports3 days ago

Fortnite: Epic Vaults Rocket Launchers, Cuddlefish & Explosive Bows From Competitive

Esports4 days ago

Don’t Miss Out on the Rogue Energy x Esports Talk Giveaway!

Esports3 days ago

Gamers Club and Riot Games Organize Women’s Valorant Circuit in Latin America

Esports4 days ago

Fortnite: DreamHack Cash Cup Extra Europe & NA East Results

Blockchain4 days ago

CoinSmart Appoints Joe Tosti as Chief Compliance Officer

Blockchain5 days ago

Bitfinex-Hacker versenden BTC im Wert von 750 Millionen USD

Blockchain4 days ago

April Continuum Blockchain Legislation Summit ContinuumBlockLegs

Blockchain3 days ago

15. BNB Burn: Binance zerstört Coins im Wert von 600 Mio. USD

Fintech5 days ago

Zip Co raises $400 million for international expansion

Esports4 days ago

2021 Call of Duty Mobile World Championship Announced

Esports4 days ago

Position 5 Faceless Void is making waves in North American Dota 2 pubs after patch 7.29

Fintech4 days ago

Mambu research reveals global consumers are hesitant to use Open Banking

Esports5 days ago

COD Mobile Season 3 Tokyo Escape

Esports5 days ago

Fortnite: Mero Joins FNCS-Winning Teammates On ENDLESS

Esports3 days ago

LoL gameplay design director pulled, transferred to Riot’s MMO

Blockchain5 days ago

Ethereum in Blockchain Software Development

Trending